ACS Nano, Год журнала: 2025, Номер unknown
Опубликована: Апрель 7, 2025
The dysregulated macrophage phenotype, as the main cause of colitis, not only enhanced oxidative stress to exacerbate inflammatory responses but was closely related with gut microbial dysbiosis. It needed simultaneously address three issues for effective treatment it satisfied. Here, we developed "three-birds-one-stone" probiotics, named Se@EcN-C2/A2, colitis treatment. Escherichia coli Nissle 1917 (EcN), a clinically approved probiotic, used intracellularly synthesize selenium (Se) nanoparticles by biomineralization, giving Se@EcN. Coating glycol chitosan and sodium alginate on surface Se@EcN (Se@EcN-C2/A2) endowed probiotics high resistance harsh gastrointestinal tract environment strong adhesion targeting ability inflamed site colon facilitate uptake M1 macrophages. Se@EcN-C2/A2 metabolized SeCys2 MetSeCys be involved in synthesis GPX2 TXNRD1, which led reaction oxygen species clearance inhibit Toll-like receptor nuclear factor κB signaling pathways suppress response polarize macrophages M2 phenotypes activating PI3K/AKT pathways. In DSS-induced mice, exerted satisfactory therapeutic prophylactic effects, including scavenging regulating restore barrier functions. Moreover, living probiotic EcN effectively regulated dysbiosis decreasing abundance Escherichia-Shigella increasing Lactobacillus Bifidobacterium.
Язык: Английский